摘要
目的评价恩替卡韦联合胸腺肽α1治疗慢性乙型肝炎的疗效。方法检索2005—2014年4月Pub Med、Cochrane Library、OVID、Springer Link、中国知网、中国生物医学文献数据库、万方数据医学网及维普网,根据纳入标准、排除标准,对入选的10篇随机对照试验(RCT)的研究结果采用Rev Man5.2软件进行分析。结果与对照组相比,实验组能更显著地提高ALT复常率、HBV DNA转阴率、HBe Ag转阴率和HBe Ag血清转换率,相对危险度(RR)分别为1.13[95%CI(1.06,1.21),Z=3.61,P=0.000 3],1.19[95%CI(1.09,1.30),Z=3.83,P=0.000 1〗、2.25[95%CI(1.52,3.33),Z=4.04,P<0.0001]和2.31[95%CI(1.83,2.92),Z=7.06,P<0.000 01];且无明显不良反应。结论恩替卡韦联合胸腺肽α1治疗慢性乙型肝炎能有效增加恩替卡韦单药抗病毒疗效,但确切疗效尚需更多临床研究加以证实。
Objective It is to value the effect of entecavir-thymosin alpha-1 combination therapy for chronic hepatitis B.Methods The papers were searched in the database of the PubM ed,Cochrane Library,OVID,SpringerL ink,CNKI,the Chinese Biomedical Database（ CBM）,Wanfangdata and CQVIP according to inclusion criteria and exclusion criteria from 2005 to April 2014. The findings of the selected ten randomized controlled trials（ RCT） were analyzed by RevM an 5. 2 Software. Results Compared with the control group,the ALT normalization rate,HBV DNA negative rate,HBeA g negative rate and HBeA g seroconversion rate of experimental group were significantly improved： RR were 1. 13 [95% CI（ 1. 06,1. 21）,Z = 3. 61,P =0. 000 3〗,1. 19 [95% CI（ 1. 09,1. 30）,Z = 3. 83,P = 0. 000 1],2. 25 [95% CI（ 1. 52,3. 33）,Z = 4. 04,P〈0. 000 1] and2. 31 [95% CI（ 1. 83,2. 92）,Z = 7. 06,P〈0. 000 01]. The injection of thymosin alpha-1 was no significant adverse events. Conclusion Entecavir-thymosin alpha-1 combination therapy is more effective in the HBV DNA reduction,increase of serum HBeA g negative rate,conversion rate and ALT normalization rate and without increasing drug adverse reactions compared with entecavir. More RCTs of high quality and large scale are required to verify this conclusion.
出处
《现代中西医结合杂志》
CAS
2015年第9期913-916,929,共5页
Modern Journal of Integrated Traditional Chinese and Western Medicine
基金
北京市卫生系统高层次卫生技术人才培训资助项目(2011-2-20)
"十二五"重大科技专项基金资助项目(2014ZX10002002-001-002)
